TOP TEN perturbations for 40093_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40093_at
Selected probe(set): 40093_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40093_at (40093_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)

Relative Expression (log2-ratio):4.180168
Number of Samples:2 / 5
Experimental expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium.
Control expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant mixed Mullerian tumor of the endometrium.

expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)

Relative Expression (log2-ratio):3.6395397
Number of Samples:2 / 20
Experimental expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium.
Control expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the endometrium.

expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-3.3489895
Number of Samples:2 / 5
Experimental expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):2.8321056
Number of Samples:51 / 2
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):2.7713718
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (carcinoma, NOS; primary) / expO ovary cancer study 1 (adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.744485
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).
Control expO ovary cancer study 1 (adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with adenocarcinoma (NOS).

expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.741272
Number of Samples:6 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.
Control expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).

ovarian tumor study 28 (serous cystadenocarcinoma) / ovarian tumor study 28 (carcinosarcoma)

Relative Expression (log2-ratio):2.7260733
Number of Samples:71 / 2
Experimental ovarian tumor study 28 (serous cystadenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma.
Control ovarian tumor study 28 (carcinosarcoma)
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma.

expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-2.6801386
Number of Samples:3 / 5
Experimental expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (clear cell adenocarcinoma)

Relative Expression (log2-ratio):-2.5643053
Number of Samples:2 / 6
Experimental ovarian tumor study 28 (carcinosarcoma)
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma.
Control ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.